fig4

From: Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression

Figure 4. THZ2/JQ1 exhibits therapeutic potential in TMZ-resistant GBM cells. (A) IC₅₀ values of TMZ in U87MG and U87MG-R cells; (B) Effects of 1 mM TMZ treatment for 48 h on apoptosis in U87MG and U87MG-R cells; (C and D) Effects of different concentrations of THZ2 (C) and JQ1 (D) on U87MG-R cell viability; (E) Effects of 0.25 μM THZ2 treatment for 48 h on apoptosis in U87MG and U87MG-R cells. Data are presented as mean ± SD from three independent experiments (n = 3). ns: No significant; ^**P < 0.01; ^***P < 0.001. Statistical significance was assessed using Student’s t-test or two-way ANOVA. TMZ: Temozolomide; GBM: glioblastoma; SD: standard deviation; ANOVA: analysis of variance.